8-K: Clene Demonstrates Strengthened ALS Survival Benefit with CNM-Au8 Treatment in New Analysis

Clene Inc. announces new data showing CNM-Au8 treatment delivers a significant survival advantage for people living with ALS, based on a cross-regimen analysis of the HEALEY ALS Platform Trial.

Summary

• Clene Inc. announced new evidence from a cross-regimen analysis of the HEALEY ALS Platform Trial, indicating a significant survival benefit for ALS patients treated with CNM-Au8 30 mg.
• The analysis compared survival in participants who received CNM-Au8 30 mg (Regimen C) to those in Regimen A, using the same randomization criteria.
• The study found that the CNM-Au8 group achieved a median survival of 951 days compared to 753 days in the comparator group, a gain of 198 days (6.5 months).
• A covariate-adjusted Restricted Mean Survival Time (RMST) improvement of 124 days (4.1 months) was observed (95% CI: 3 to 245 days, p=0.045).
• In participants with moderate to severe ALS (baseline serum NfL > 33 pg/mL and TRICALS risk score between 6.5 and 2.5), median survival improved from 589 days to 951 days, an 11.9 month gain.
• This subgroup also experienced a 44% decrease in mortality risk (Cox HR: 0.556, 95% CI: 0.367-0.842, p=0.006).
• In a subset meeting planned Phase 3 RESTORE-ALS trial enrollment criteria, median survival improved from 628 days to 1079 days, an increase of 451 days (14.8 months).
• This subset experienced a 49% reduction in mortality risk (Cox HR: 0.514, 95% CI: 0.319-0.830, p=0.006).
• The company plans to launch the Phase 3 RESTORE-ALS study in mid-2025 to confirm these findings.

Sentiment

Score: 8

Explanation: The document presents positive clinical trial results, suggesting a potential breakthrough in ALS treatment. The planned Phase 3 trial further supports a positive outlook, although risks remain regarding regulatory approval and funding.

Positives

• CNM-Au8 demonstrates a statistically significant survival benefit for ALS patients in a cross-regimen analysis.
• The survival benefit is particularly pronounced in patients with moderate to severe ALS.
• The results support the planned Phase 3 RESTORE-ALS trial, which aims to confirm these findings.
• The innovative design of the HEALEY ALS Platform Trial has enabled extraction of clear and meaningful survival data.

Negatives

• The analysis is a post hoc analysis, which may be viewed as less definitive than a pre-planned analysis.
• Regimen A was stopped prematurely for futility, which could introduce bias into the comparison.

Risks

• The Phase 3 RESTORE-ALS trial is still required to confirm the findings and obtain regulatory approval.
• Regulatory agencies may require additional data or have concerns about the study design.
• The company's ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates is a risk.

Future Outlook

The company plans to launch the Phase 3 RESTORE-ALS study in mid-2025 and discuss the findings with the FDA as they advance toward commercialization.

Management Comments

• Rob Etherington, President and CEO of Clene, stated that the significant survival advantage demonstrated by CNM-Au8 reinforces its potential to extend life for people living with ALS and validates their strategic direction.
• Merit Cudkowicz, M.D., M.S.c., Principal Investigator and sponsor of the HEALEY ALS Platform Trial, said that the innovative design of the trial has enabled them to extract clear and meaningful survival data that helps make decisions about CNM-Au8 drug development.

Industry Context

The announcement is significant in the context of ALS treatment, as there is a high unmet need for effective therapies that can extend survival and improve the quality of life for patients. The HEALEY ALS Platform Trial is an innovative approach to drug development in ALS, allowing for multiple treatments to be tested simultaneously.

Comparison to Industry Standards

• The reported median survival increase of 6.5 months in the overall analysis set and up to 14.8 months in a specific subset of patients is a notable improvement compared to existing ALS treatments.
• Riluzole, one of the standard treatments for ALS, has been shown to extend survival by approximately 2-3 months in some studies.
• Edaravone, another approved ALS drug, has shown modest benefits in slowing disease progression in certain patient populations.
• The results of the CNM-Au8 trial appear promising when compared to the effects of these established treatments, particularly in the identified subgroups.

Stakeholder Impact

• Positive impact on ALS patients and their families due to the potential for extended survival.
• Potential positive impact on Clene Inc.'s shareholders if the Phase 3 trial is successful and the drug is approved.
• Potential impact on the broader ALS treatment landscape, potentially shifting treatment paradigms.

Next Steps

• Launch of the Phase 3 RESTORE-ALS study in mid-2025.
• Discussions with the FDA regarding the clinical trial results and potential commercialization.

Key Dates